COST-EFFECTIVENESS ANALYSIS OF INFLIXIMAB, ADALIMUMAB, AND CERTOLIZUMAB FOR CROHN'S DISEASE: A MARKOV MODEL STUDY

被引：0
|
作者：
Ajala, C. [1 ]
Zapata, Villa L. [2 ]
机构：
[1] Univ Georgia, Coll Pharm, Athens, GA USA
[2] Univ Georgia, Coll Pharm, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE19
引用
收藏
页码：S60 / S60
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Vedolizumab Compared to Adalimumab for Patients with Crohn's Disease Aft er Loss of Response to Infliximab: A Markov Model
    Schneider, Yecheskel
    Saumoy, Monica
    Gold, Stephanie L.
    Cohen-Mekelburg, Shirley
    Bosworth, Brian
    Scherl, Ellen J.
    Steinlauf, Adam
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S335 - S336
  • [2] The cost-effectiveness of infliximab in Crohn's disease
    Smart, Claire
    Selinger, Christian P.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (05) : 589 - 598
  • [3] COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB VS. CERTOLIZUMAB MAINTENANCE THERAPIES FOR MODERATE TO SEVERE CROHN'S DISEASE
    Johnson, S.
    Kaltenboeck, A.
    Horn, C.
    Mulani, P.
    Majethia, S.
    Chao, J.
    VALUE IN HEALTH, 2009, 12 (03) : A59 - A59
  • [4] CERTOLIZUMAB PEGOL IN CROHN'S DISEASE REFRACTORY TO INFLIXIMAB AND ADALIMUMAB
    Jose, Morales Lara Ma
    Penella Monica, Martinez
    Guzman Diana, Lacruz
    Vidal Vanessa, Jorge
    Maneiro Vicente, Santaclara
    Sanchez Senador, Moran
    del Carmen, Mira Sirvent Ma
    ATENCION FARMACEUTICA, 2009, 11 (03): : 178 - 180
  • [5] COST-EFFECTIVENESS OF ADALIMUMAB FOR TREATMENT OF CROHN'S DISEASE IN GERMANY
    Yang, M.
    Yang, M.
    Skup, M.
    Zhou, Z. Y.
    Hengst, N.
    Wolff, M.
    Mulani, P. M.
    Chao, J.
    VALUE IN HEALTH, 2012, 15 (07) : A329 - A329
  • [6] Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
    Kaplan, G. G.
    Hur, C.
    Korzenik, J.
    Sands, B. E.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) : 1509 - 1520
  • [7] Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
    Osterman, Mark T.
    Haynes, Kevin
    Delzell, Elizabeth
    Zhang, Jie
    Bewtra, Meenakshi
    Brensinger, Colleen
    Chen, Lang
    Xie, Fenlong
    Curtis, Jeffrey R.
    Lewis, James D.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (05) : 811 - U137
  • [8] Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
    Haynes, Kevin
    Osterman, Mark T.
    Delzell, Elizabeth
    Zhang, Jie
    Bewtra, Meenakshi
    Brensinger, Colleen
    Chen, Lang
    Xie, Fenlong
    Curtis, Jeffrey R.
    Lewis, James D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 359 - 359
  • [9] COST-EFFECTIVENESS ANALYSIS OF THE USE OF ADALIMUMAB FOR THE TREATMENT OF CROHN'S DISEASE (CD) IN MEXICO
    Mayen-Herrera, E.
    Pozos, J. C.
    Yang, M.
    Cortina, D.
    VALUE IN HEALTH, 2011, 14 (07) : A548 - A548
  • [10] Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease
    Loftus, Edward V., Jr.
    Johnson, Scott J.
    Yu, Andrew P.
    Wu, Eric Q.
    Chao, Jingdong
    Mulani, Parvez M.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (11) : 1302 - 1309
12345